Novel ZEB1 expression in bladder tumorigenesis

BJU International

Volumn 107, Issue 4, 2011, Pages 656-663

  Kenney, Patrick A ^a   Wszolek, Matthew F ^a   Rieger Christ, Kimberly M ^a   Neto, Brasil Silva ^a   Gould, Justin J ^a   Harty, Niall J ^a   Mosquera, Juan Miguel ^a   Zeheb, Ron ^a,e   Loda, Massimo ^b   Darling, Douglas S ^c   Libertino, John A ^d   Summerhayes, Ian C ^b,d  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b Cell and Molecular Biology Laboratory   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

bladder cancer; microRNA; ZEB1

Indexed keywords

MICRORNA; PROTEIN ZEB1; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; URINARY BLADDER NEOPLASMS;

EID: 79551515867     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09489.x     Document Type: Article

References (38)

1. Thiery JP,. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-54
2. Thiery JP,. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15: 740-6
3. Thompson EW, Newgreen DF, Tarin D,. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 2005; 65: 5991-5; discussion 5995
4. Huber MA, Kraut N, Beug H,. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548-58
5. Miettinen PJ, Ebner R, Lopez AR, Derynck R,. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994; 127: 2021-36
6. Savagner P,. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001; 23: 912-23
7. Nawshad A, Lagamba D, Polad A, Hay ED,. Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs 2005; 179: 11-23
8. Bellovin DI, Bates RC, Muzikansky A, Rimm DL, Mercurio AM,. Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res 2005; 65: 10938-45
9. Baumgart E, Cohen MS, Silva Neto B, et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 2007; 13: 1685-94
10. Peinado H, Olmeda D, Cano A,. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415-28
11. Zhang Z, Xie D, Li X, et al. Significance of TWIST expression and its association with E-cadherin in bladder cancer. Hum Pathol 2007; 38: 598-606 (Pubitemid 46399887)
12. Fondrevelle ME, Kantelip B, Reiter RE, et al. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urol Oncol 2008; 27: 268-76
13. Elias MC, Tozer KR, Silber JR, et al. TWIST is expressed in human gliomas and promotes invasion. Neoplasia 2005; 7: 824-37
14. Kwok WK, Ling MT, Lee TW, et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005; 65: 5153-62
15. Kyo S, Sakaguchi J, Ohno S, et al. High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum Pathol 2006; 37: 431-8
16. Lee TK, Poon RT, Yuen AP, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 2006; 12: 5369-76
17. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-39
18. Spoelstra NS, Manning NG, Higashi Y, et al. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res 2006; 66: 3893-902
19. Singh M, Spoelstra NS, Jean A, et al. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol 2008; 21: 912-23
20. Spaderna S, Schmalhofer O, Wahlbuhl M, et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 2008; 68: 537-44
21. Spaderna S, Schmalhofer O, Hlubek F, et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006; 131: 830-40
22. Aigner K, Dampier B, Descovich L, et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007; 26: 6979-88
23. Aigner K, Descovich L, Mikula M, et al. The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS Lett 2007; 581: 1617-24
24. Furukawa C, Daigo Y, Ishikawa N, et al. Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. Cancer Res 2005; 65: 7102-10
25. Cano A, Nieto MA,. Non-coding RNAs take centre stage in epithelial-to-mesenchymal transition. Trends Cell Biol 2008; 18: 357-9
26. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601
27. Korpal M, Lee ES, Hu G, Kang Y,. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-4
28. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-9
29. Liu Y, El-Naggar S, Darling DS, Higashi Y, Dean DC,. Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development 2008; 135: 579-88
30. Park SM, Gaur AB, Lengyel E, Peter ME,. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907
31. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ,. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007; 67: 7972-6
32. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C,. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006; 24: 778-89
33. Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005; 11: 4044-55
34. Wszolek MF, Rieger-Christ KM, Kenney PA, et al. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol 2009 [Epub ahead of print]
35. Sayan AE, Griffiths TR, Pal R, et al. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci USA 2009; 106: 14884-9
36. Feber A, Clark J, Goodwin G, et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 2004; 23: 1627-30
37. Oeggerli M, Tomovska S, Schraml P, et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004; 23: 5616-23 (Pubitemid 39093039)
38. Neely LA, Rieger-Christ KM, Neto BS, et al. A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol 2010; 28: 39-48